Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan, Yi-Dong | - |
dc.contributor.author | Kim, Dae Hwan | - |
dc.contributor.author | Sung, Jun Ho | - |
dc.contributor.author | Yong, Chul Soon | - |
dc.contributor.author | Choi, Han Gon | - |
dc.date.accessioned | 2021-06-23T12:39:40Z | - |
dc.date.available | 2021-06-23T12:39:40Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.issn | 1873-3476 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/39447 | - |
dc.description.abstract | As with many other anti-cancer agents, docetaxel is a substrate for ATP-binding cassette transporters such as P-glycoprotein and its metabolism is mainly catalysed by CYP3A. In order to improve the oral bioavailability of docetaxel, a component of turmeric, curcumin, which can down-regulate the intestinal P-glycoprotein and CYP3A protein levels, was used for the pre-treatment of rats before the oral administration of docetaxel. Curcumin (100 mg/kg) did not significantly modify the pharmacokinetics of docetaxel when given orally 30 min before the administration of docetaxel. However, the C-max of docetaxel in rats pre-treated with curcumin for four consecutive days was significantly increased (p < 0.01) by about 10 times compared to that of the docetaxel control, and the area under the plasma concentration-time curve (AUC) was about eight times higher than that of the control. Consequently, the absolute bioavailability of docetaxel in the treatment group (four days of curcumin at 100 mg/kg) was about 40%, which was a significant increase of about eightfold in comparison to the control value. Thus, the oral bioavailability of docetaxel was enhanced by the co-administration of regular curcumin. It could be possible to administer docetaxel orally, besides the established iv. route. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER | - |
dc.title | Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.ijpharm.2010.08.015 | - |
dc.identifier.scopusid | 2-s2.0-77956879465 | - |
dc.identifier.wosid | 000283006700015 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v.399, no.1-2, pp 116 - 120 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.volume | 399 | - |
dc.citation.number | 1-2 | - |
dc.citation.startPage | 116 | - |
dc.citation.endPage | 120 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | ENZYMES | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Curcumin | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Bioavailability | - |
dc.subject.keywordAuthor | Pre-treatment | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0378517310006204?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.